title: Eosinophilic esophagitis: update on clinicopathological manifestations and pathophysiology.
abstract: OBJECTIVE
  Over the course of the last year, a number of studies have brought new insights into the clinical presentation, pathogenesis, and treatment of eosinophilic esophagitis, some of which will be summarized here.
  
  
  RESULTS
  This swell of research and clinical need resulted in revision of the 2007 Consensus Recommendations. In addition, new insights into key clinicopathological features including symptoms such as feeding dysfunction and histological quantification of eosinophil extracellular granules are presented. The advancement of the field is strongly supported by blinded and placebo-controlled studies of IL-5 and oral viscous budesonide as well as new large studies examining the safety of dilation.
  
  
  CONCLUSIONS
  Overall, these studies set the stage for new methodologies to understand the pathophysiology of eosinophilic esophagitis and development of novel therapies.
authors.affiliation: Digestive Health Institute, Section of Pediatric Gastroenterology, Hepatology and Nutrition, Gastrointestinal Eosinophilic Diseases Program, The Children's Hospital, National Jewish Health, Mucosal Inflammation Program, Department of Pediatrics, University of Colorado Denver School of Medicine, Aurora, Colorado, USA. Furuta.Glenn@tchden.org
authors.forename: Glenn T
authors.initials: GT
authors.lastname: Furuta
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D019819:Budesonide / Q000627:therapeutic use; D057765:Eosinophilic Esophagitis / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D004947:Esophagus / Q000473:pathology; D006801:Humans
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D019819:Budesonide